Griseofulvin (Sandoz Inc)
Welcome to the PulseAid listing for the Griseofulvin drug offered from Sandoz Inc. This Decreased Mitosis [PE],Microtubule Inhibition [PE],Tubulin Inhibiting Agent [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Sandoz Inc |
NON-PROPRIETARY NAME: | Griseofulvin |
SUBSTANCE NAME: | GRISEOFULVIN |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Decreased Mitosis [PE],Microtubule Inhibition [PE],Tubulin Inhibiting Agent [EPC] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET |
MARKETING CATEGORY NAME: | ANDA |
START MARKETING DATE: | 2013-08-07 |
END MARKETING DATE: | 0000-00-00 |
Griseofulvin HUMAN PRESCRIPTION DRUG Details:
Item Description | Griseofulvin from Sandoz Inc |
LABELER NAME: | Sandoz Inc |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 250(mg/1) |
START MARKETING DATE: | 2013-08-07 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0781-5514_27a575d3-76fb-4ade-bcac-7ced178643bb |
PRODUCT NDC: | 0781-5514 |
APPLICATION NUMBER: | ANDA091592 |
Other GRISEOFULVIN Pharmaceutical Manufacturers / Labelers: